Compare ELTK & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTK | LPCN |
|---|---|---|
| Founded | 1970 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.3M | 61.8M |
| IPO Year | 1997 | N/A |
| Metric | ELTK | LPCN |
|---|---|---|
| Price | $9.20 | $10.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 5.7K | ★ 246.3K |
| Earning Date | 03-10-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $49,310,000.00 | $4,322,693.00 |
| Revenue This Year | $18.60 | N/A |
| Revenue Next Year | $9.04 | N/A |
| P/E Ratio | $54.51 | ★ N/A |
| Revenue Growth | ★ 2.54 | N/A |
| 52 Week Low | $7.65 | $2.52 |
| 52 Week High | $12.19 | $12.37 |
| Indicator | ELTK | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 80.94 |
| Support Level | $8.64 | $10.56 |
| Resistance Level | $9.41 | $12.37 |
| Average True Range (ATR) | 0.24 | 1.06 |
| MACD | 0.11 | 0.32 |
| Stochastic Oscillator | 64.06 | 74.50 |
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.